The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).
MRV Research
Study identifies potential therapeutics target for metastatic melanoma
Researchers in the Randall Division of Cell & Molecular Biophysics have had the findings of their study into a potential therapeutics target for metastatic melanoma published in the journal Current Biology.
Exceptional Response in Brain Tumor Patient Instills Confidence in Personalized Medicine
A young man, less than 40 years old, with recurrent craniopharyngioma (pituitary tumor) harboring a BRAF V600E mutation, showed a dramatic response when treated with BRAF V600E inhibitors—85% reduction in tumor volume. This case has the “potential of completely changing the management of papillary craniopharyngiomas,” according to study author Priscilla Brastianos, MD, of the Massachusetts General Hospital (MGH) Cancer Center.
Exosome Diagnostics’ Exosomal RNA Platform Demonstrates Enrichment of Tumor-Specific Gene Changes in Response to Immunotherapy Treatment
Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced new data demonstrating the novel ability of its proprietary exosomal RNA (exoRNA) technology platform to enrich cancer specific exosomes in order to more precisely determine tumor-specific gene changes in response to immunotherapy treatment.